Cargando…

Immune phenotype of patients with stage IV metastatic inflammatory breast cancer

BACKGROUND: Inflammatory breast cancer (IBC) is a rare but aggressive carcinoma characterized by severe erythema and edema of the breast, with many patients presenting in advanced metastatic disease. The “inflammatory” nature is not due to classic immune-mediated inflammation, but instead results fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Sandra V., MacFarlane, Alexander W., Jillab, Mowafaq, Arisi, Maria F., Yearley, Jennifer, Annamalai, Lakshmanan, Gong, Yulan, Cai, Kathy Q., Alpaugh, R. Katherine, Cristofanilli, Massimo, Campbell, Kerry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709446/
https://www.ncbi.nlm.nih.gov/pubmed/33267869
http://dx.doi.org/10.1186/s13058-020-01371-x
Descripción
Sumario:BACKGROUND: Inflammatory breast cancer (IBC) is a rare but aggressive carcinoma characterized by severe erythema and edema of the breast, with many patients presenting in advanced metastatic disease. The “inflammatory” nature is not due to classic immune-mediated inflammation, but instead results from tumor-mediated blockage of dermal lymphatic ducts. Previous work has shown that expression of PD-L1 on tumor cells can suppress T cell activation in triple-negative (TN) non-IBC breast cancer. In the present work, we investigated immune parameters in peripheral blood of metastatic IBC patients to determine whether cellular components of the immune system are altered, thereby contributing to pathogenesis of the disease. These immune parameters were also compared to PD-1 and PD-L1 expression in IBC tumor biopsies. METHODS: Flow cytometry-based immune phenotyping was performed using fresh peripheral blood from 14 stage IV IBC patients and compared to 11 healthy age-similar control women. Immunohistochemistry for CD20, CD3, PD-1, and PD-L1 was performed on tumor biopsies of these metastatic IBC patients. RESULTS: IBC patients with Stage IV disease had lymphopenia with significant reductions in circulating T, B, and NK cells. Reductions were observed in all subsets of CD4(+) T cells, whereas reductions in CD8(+) T cells were more concentrated in memory subsets. Immature cytokine-producing CD56(bright) NK cells expressed higher levels of FcγRIIIa and cytolytic granule components, suggesting accelerated maturation to cytolytic CD56(dim) cells. Immunohistochemical analysis of tumor biopsies demonstrated moderate to high expression of PD-1 in 18.2% of patients and of PD-L1 in 36.4% of patients. Interestingly, a positive correlation was observed between co-expression levels of PD-L1 and PD-1 in tumor biopsies, and higher expression of PD-L1 in tumor biopsies correlated with higher expression of cytolytic granule components in blood CD4(+) T cells and CD56(dim) NK cells, and higher numbers of CD8(+) effector memory T cells in peripheral blood. PD-1 expression in tumor also correlated with increased infiltration of CD20(+) B cells in the tumor. CONCLUSIONS: Our results suggest that while lymphocyte populations are severely compromised in stage IV IBC patients, an immune response toward the tumor had occurred in some patients, providing biological rationale to evaluate PD-1/PD-L1 immunotherapies for IBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-020-01371-x.